|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Vii_V_Healthcare
|
|
gptkbp:activities
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
integrase strand transfer inhibitor
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
HIV-1 infection
HIV-2 infection
|
|
gptkbp:contains
|
gptkb:abacavir
gptkb:lamivudine
dolutegravir
|
|
gptkbp:contraindication
|
hypersensitivity to abacavir
|
|
gptkbp:dosage_form
|
fixed-dose combination
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Triumeq
|
|
gptkbp:ingredients
|
gptkb:lamivudine
abacavir sulfate
dolutegravir sodium
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:carbamazepine
gptkb:rifampin
methadone
oxcarbazepine
|
|
gptkbp:is_used_for
|
treatment of HIV
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Vii_V_Healthcare
|
|
gptkbp:marketed_as
|
gptkb:Triumeq
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:provides_information_on
|
WHO guidelines
first-line therapy
second-line therapy
CDC guidelines
AID Sinfo guidelines
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
liver toxicity
insomnia
lactic acidosis
renal impairment
pancreatitis
hypersensitivity reaction
|
|
gptkbp:storage
|
room temperature
|